Short answer
Oruka Therapeutics, Inc. (ORKA) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 text contains only incorporation-by-reference and liability disclaimers.
Oruka Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 text contains only incorporation-by-reference and liability disclaimers
- No earnings figures, reporting period, or operating results provided; investor-relevant details likely reside in the referenced exhibit
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss widened to $41.2M from $24.6M as R&D rose to $43.3M from $24.1M
- $1.1B cash, equivalents and securities expected to fund operations through ORKA-001’s anticipated BLA filing
- EVERLAST-A Week 28 data due 3Q 2026 and 52-week durability data in December 2026
- EVERLAST-B fully enrolled with Week 16 data expected in 4Q 2026, supporting potential Phase 3 initiation in 1H 2027
- ORCA-SPLASH adds a Phase 2 hidradenitis suppurativa program; ORKA-004 clinical entry expected in 4Q 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oruka Therapeutics, Inc. 8-K filings
Get the next ORKA 8-K as it lands
Follow ORKA for push alerts, or ask the research agent what this filing means.